Global Tumor Ablation Market and Forecast to 2032

GURUGRAM, India - Nov. 19, 2025 - PRLog -- The global tumor ablation market is projected to reach USD 4.15 Billion by 2032, from USD 1.67 Billion in 2024, reflecting sustained momentum in minimally invasive oncology interventions. Tumor ablation, an image-guided, minimally invasive technique, leverages energy modalities such as radiofrequency, microwave, cryotherapy, and laser to selectively destroy cancerous tissue while preserving surrounding healthy structures. Its high precision and lower procedural burden have positioned it as a preferred option for treating small tumors, particularly in the liver, lungs, and kidneys.

The growing adoption of precision oncology and personalized treatment pathways continues to accelerate demand for these modalities, as clinicians increasingly seek targeted solutions that minimize adverse effects and improve patient outcomes. Additionally, the technological advancements to enhance accuracy, portability, and cost-effectiveness are likely to encourage market players to constantly improve and launch advanced tumor ablation devices. For instance, in December 2024, AngioDynamics, Inc. received U.S. Food and Drug Administration (FDA) 510(k) clearance for the NanoKnife System for prostate tissue ablation, underscoring the expanding clinical utility and regulatory momentum within the sector.

Recent Developments

• In February 2025, Boston Scientific Corporation received CE Mark approval for the FARAWAVE NAV Ablation Catheter, a navigation technology designed for the treatment of paroxysmal atrial fibrillation (PFA), and the new FARAVIEW Module.
• In May 2025, Stryker announced that its OptaBlate basivertebral nerve ablation system (OptaBlate BVN) received 510(k) clearance from the U.S. Food and Drug Administration. OptaBlate BVN is used in a targeted minimally invasive procedure providing long-lasting vertebrogenic pain relief.
• In March 2024, Medtronic plc received U.S. Food and Drug Administration (FDA) 510(k) clearance for its OsteoCool 2.0 bone tumor ablation system for the treatment of painful bone metastases and benign bone tumors such as osteoid osteoma.

Apelo Consulting report titled "Global Tumor Ablation Market (By Technology, Treatment Mode, Application, End User, Region), Company Profiles, Product Portfolio, Recent Developments, Key Trends and Market Dynamics – Global Forecast to 2032" provides a complete assessment of the fast–evolving, high–growth Global Tumor Ablation landscape.

For more details, please visit: https://apeloconsulting.com/reports/